Patients with beta-thalassemia major (also known as Cooley's anemia) have a reduction or absence of beta protein in their hemoglobin, resulting in severe anemia, which requires regular blood ... A domestically developed gene-editing therapy has successfully treated patients with beta-thalassemia, allowing them to live without the need for lifelong blood transfusions, according to a study ... Novo Nordisk (NYSE:NVO) is advancing etavopivat through late stage clinical trials as a potential therapy for thalassemia.

Understanding the Context

The treatment is under ongoing regulatory review, focused on both beta and ... Healio: Exa-cel dramatically improves quality of life for sickle cell disease, beta-thalassemia Please provide your email address to receive an email when new articles are posted on . Patients with sickle cell disease and beta-thalassemia reported substantial improvements in quality of life ... An essential factor in distinguishing thalassemia phenotypes is transfusion dependence.

Key Insights

While beta-thalassemia major requires life-long blood transfusions for survival, non-transfusion-dependent ... Aqvesme is expected to be available in late January 2026. The Food and Drug Administration (FDA) has approved Aqvesme™ (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia ... Healio: ‘Extremely encouraging’: Exa-cel benefits kids with sickle cell disease, beta thalassemia Please provide your email address to receive an email when new articles are posted on . Children with beta thalassemia achieved transfusion independence after being treated with exa-cel.

Final Thoughts

Children with ... Seeking Alpha: Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript News Medical: Gene editing therapy exa-cel improves quality of life in sickle cell disease and beta thalassemia In the beta thalassemia study, Dr. de la Fuente and his colleagues used two quality of life scales to evaluate outcomes in adult patients and two quality of life scales for adolescent patients. Unlike ...

Gene editing therapy exa-cel improves quality of life in sickle cell disease and beta thalassemia